AtriCure, Inc. (NASDAQ:ATRC) Shares Sold by Emerald Advisers LLC

Emerald Advisers LLC cut its position in shares of AtriCure, Inc. (NASDAQ:ATRC) by 77.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 89,098 shares of the medical device company’s stock after selling 300,738 shares during the quarter. Emerald Advisers LLC owned 0.18% of AtriCure worth $2,723,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of ATRC. LPL Financial LLC grew its stake in AtriCure by 5.4% in the fourth quarter. LPL Financial LLC now owns 11,465 shares of the medical device company’s stock valued at $350,000 after purchasing an additional 584 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of AtriCure in the fourth quarter worth about $321,000. Sei Investments Co. lifted its position in shares of AtriCure by 6.1% in the fourth quarter. Sei Investments Co. now owns 107,290 shares of the medical device company’s stock worth $3,279,000 after buying an additional 6,152 shares during the last quarter. American Century Companies Inc. acquired a new stake in shares of AtriCure in the fourth quarter worth about $516,000. Finally, Intech Investment Management LLC lifted its position in shares of AtriCure by 41.4% in the fourth quarter. Intech Investment Management LLC now owns 21,520 shares of the medical device company’s stock worth $658,000 after buying an additional 6,306 shares during the last quarter. 99.11% of the stock is owned by institutional investors.

Insider Activity

In other news, Director Karen Prange sold 6,100 shares of the company’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $38.12, for a total value of $232,532.00. Following the sale, the director now directly owns 17,828 shares in the company, valued at approximately $679,603.36. This represents a 25.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 3.20% of the company’s stock.

Wall Street Analysts Forecast Growth

ATRC has been the subject of a number of analyst reports. Piper Sandler boosted their price target on AtriCure from $40.00 to $50.00 and gave the stock an “overweight” rating in a research report on Thursday, February 13th. JPMorgan Chase & Co. boosted their price objective on AtriCure from $40.00 to $51.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 11th. Stifel Nicolaus boosted their price objective on AtriCure from $36.00 to $48.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Oppenheimer boosted their price objective on AtriCure from $36.00 to $45.00 and gave the stock an “outperform” rating in a research report on Thursday, February 13th. Finally, JMP Securities reissued a “market outperform” rating and set a $60.00 price objective on shares of AtriCure in a research report on Monday, February 10th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $51.56.

AtriCure Trading Down 3.7 %

ATRC stock opened at $33.54 on Monday. AtriCure, Inc. has a 1-year low of $18.94 and a 1-year high of $43.11. The firm has a market cap of $1.64 billion, a P/E ratio of -35.30 and a beta of 1.53. The business’s 50 day moving average is $38.22 and its 200-day moving average is $33.77. The company has a current ratio of 3.65, a quick ratio of 2.62 and a debt-to-equity ratio of 0.13.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.